Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease: Results from a prospective study (SECURE)

被引：0
|
作者：
Strik, A. [1 ]
van de Vrie, W. [2 ]
Bloemsaat-Minekus, J. [3 ]
Nurmohamed, M. [4 ]
Bossuyt, P. [5 ]
Bodelier, A. [6 ]
Rispens, T. [7 ]
van Megen, Y. [3 ]
D'Haens, G. [1 ]
机构：
[1] Acad Med Ctr, Gastroenterol & Hepatol, Amsterdam, Netherlands
[2] Albert Schweitzer Hosp, Dept Gastroenterol & Hepatol, Dordrecht, Netherlands
[3] Mundipharma Pharmaceut BV, Hoevelaken, Netherlands
[4] Amsterdam Rheumatol & Immunol Ctr, Amsterdam, Netherlands
[5] Imelda Hosp, Bonheiden, Belgium
[6] Amphia Hosp Breda Loc Langendijk, Breda, Netherlands
[7] Tytgat Inst Intestinal & Liver Res, AMC, Amsterdam, Netherlands
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P724
引用
收藏
页码：S477 / S478
页数：2
相关论文
共 50 条
  • [21] Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
    Nakagawa, Tomoo
    Kobayashi, Taku
    Nishikawa, Kiyohiro
    Yamada, Fumika
    Asai, Satoshi
    Sameshima, Yulcinori
    Suzuki, Yasuo
    Watanabe, Mamoru
    Hibi, Toshifumi
    INTESTINAL RESEARCH, 2019, 17 (04) : 504 - 515
  • [22] Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
    Guerra Veloz, Maria Fernanda
    Vazquez Moron, Juan Maria
    Belvis Jimenez, Maria
    Manrique, Hector Pallares
    Valdes Delgado, Teresa
    Castro Laria, Luisa
    Maldonado Perez, Belen
    Benitez Roldan, Antonio
    Perea Amarillo, Raul
    Merino, Vicente
    Caunedo Alvarez, Angel
    Arguelles-Arias, Federico
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2018, 110 (09) : 564 - 570
  • [23] Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13
    Parigi, Tommaso Lorenzo
    D'Amico, Ferdinando
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (01) : 37 - 46
  • [24] CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease
    Albshesh, Ahmad
    Ben-Horin, Shomron
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) : 971 - 978
  • [25] A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
    Farkas, Klaudia
    Molnar, Tamas
    IMMUNOTHERAPY, 2018, 10 (02) : 107 - 117
  • [26] DISEASE WORSENING AND SAFETY IN PATIENTS SWITCHING FROM ORIGINATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN THE NOR-SWITCH STUDY: EXPLORATIVE ANALYSIS OF RA PATIENTS
    Goll, G. L.
    Olsen, I. C.
    Bolstad, N.
    Jorgensen, K. K.
    Lorentzen, M.
    Mork, C.
    Jahnsen, J.
    Haavardsholm, E. A.
    Kvien, T. K.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 549 - 550
  • [27] Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: Multicentre study at 12 months results
    Guerra Veloz, M. F.
    Belvis Jimenez, M.
    Vazquez Moron, J. M.
    Pallares Manrique, H.
    Valdes Delgado, T.
    Castro Laria, L.
    Maldonado Perez, B.
    Perea Amarillo, R.
    Merino, V.
    Caunedo Alvarez, A.
    Argueelles-Arias, F.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S368 - S369
  • [28] Patients' perspectives on switching from reference infliximab to CT-P13 biosimilar in patients with inflammatory bowel disease: A 12-month prospective observational cohort study
    Petitdidier, N.
    Gagniere, C.
    Rentien, A. L.
    Tannoury, J.
    Le Baleur, Y.
    Mesli, F.
    Sobhani, I.
    Amiot, A.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S373 - S374
  • [29] Infliximab biosimilar CT-P13 in inflammatory bowel disease patients that require intensification treatment
    Gompertz, M.
    Alfaro, I.
    Ricart, E.
    Lopez, A.
    Panes, J.
    Gallego, M.
    Barastegui, R.
    Giner, A.
    Vara, A.
    Masamunt, M.
    Ordas, I.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S427 - S428
  • [30] Clinical outcomes of switching from originator to biosimilar infliximab in inflammatory bowel disease
    Lin, M. C-P
    Fauzi, M. N. B. M.
    Subramaniam, K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 149 - 150
12345